Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Novartis Pharmaceuticals Corporation Stories

2014-04-03 08:29:00

- More than 50 abstracts highlight breadth and depth of Novartis Oncology pipeline and ability to test various combinations early to target multiple pathways EAST HANOVER, N.J., April 3, 2014 /PRNewswire/ -- Novartis announced today that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research (AACR), April 5-9, 2014 in San Diego, CA. The AACR annual meeting highlights basic, translational...

2014-03-26 16:25:46

- Data showed investigational treatment LDK378 (ceritinib) also achieved a median progression-free survival of seven months EAST HANOVER, N.J., March 26, 2014 /PRNewswire/ -- Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven...

2014-03-22 08:21:21

- FEATURE and JUNCTURE data show secukinumab delivered significant skin clearance at week 12(1,2) EAST HANOVER, N.J., March 22, 2014 /PRNewswire/ -- Novartis today announced results from the Phase III FEATURE and JUNCTURE studies showing secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 response...

2014-03-21 16:23:03

- First-in-class medicine approved for CIU, a burdensome skin condition that can cause hives, severe itch, and swelling that can last many months and years EAST HANOVER, N.J., March 21, 2014 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) approved Xolair(®) (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for patients 12 years of age and older who remain symptomatic despite treatment with...

2014-01-08 20:21:27

- Patient safety and well-being are highest priority at Novartis Pharmaceuticals Corporation (NPC) EAST HANOVER, N.J., Jan. 8, 2014 /PRNewswire/ -- Patient safety and well-being are the highest priority at Novartis Pharmaceuticals Corporation (NPC). NPC is dedicated to improving patient health and supports patient medication adherence programs integral to this goal. These include outreach by pharmacies aimed at helping patients appropriately take their medicines as prescribed...

2013-12-08 20:20:38

- ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Gleevec(1) EAST HANOVER, N.J., Dec. 8, 2013 /PRNewswire/ -- Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna(®) (nilotinib) compared to Gleevec(®) (imatinib mesylate) tablets* at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient...

2013-12-07 08:20:47

-- Data at ASH show increased scientific understanding of CTL019 and its potential role in the treatment of certain types of lymphocytic leukemia(1,2,3,4) EAST HANOVER, N.J., Dec. 7, 2013 /PRNewswire/ -- Novartis is highlighting new research from members of the faculty at the University of Pennsylvania's Perelman School of Medicine (Penn) on the investigational chimeric antigen receptor (CAR) therapy, CTL019. Several studies being presented at the American Society of Hematology (ASH) annual...

2013-09-26 23:34:10

Novartis Pharmaceuticals keeps moving forward with its green and sustainable practices by incorporating cutting edge solar technology provided by Onyx Solar, a leading company in Building Integrated Photovoltaics (BIPV). The Photovoltaic Skylight generates enough energy to supply the lighting of more than 600 houses. New York, NY (PRWEB) September 26, 2013 Onyx Solar has completed the installation of the largest photovoltaic skylight in the World, a PV double skylight sizing 27,500 sqf...

2013-06-27 20:22:17

- Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer's; 24-week study showed statistically significant improvement in overall cognition and function compared to 4.6 mg/24h dose EAST HANOVER, N.J., June 27, 2013 /PRNewswire/ -- The US Food and Drug Administration (FDA) has expanded the approved indication for Exelon® Patch (rivastigmine transdermal system) to include the treatment of people with severe Alzheimer's disease (AD) with Exelon Patch...

2013-06-04 08:25:07

-- "Together in MS" tandem teams have pedaled 1,000 miles in 15 National MS Society "Bike MS" events since 2011 EAST HANOVER, N.J., June 4, 2013 /PRNewswire/ -- Phil Keoghan, host of "The Amazing Race" and founder of No Opportunity Wasted (NOW), joins Novartis Pharmaceuticals Corporation for the third year to raise awareness of multiple sclerosis (MS) through a unique campaign, called Together in MS. The campaign helps show--through participation and accomplishment--that MS does...